Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.
暂无分享,去创建一个
Hiroyuki Nishimori | James P Basilion | Wadih Arap | Renata Pasqualini | Vincenzo Paolillo | Juri G Gelovani | R. Sidman | K. Aldape | O. Bogler | M. Ozawa | G. Fuller | W. Cavenee | F. Furnari | J. Basilion | W. Arap | F. Lang | W. Driessen | H. Nishimori | R. Pasqualini | F. I. Staquicini | J. Gelovani | L. Flores | M. Alauddin | Xiaowen Liang | M. Höök | Gregory N Fuller | Mian M Alauddin | Kenneth D Aldape | Xiaowen Liang | Magnus Höök | Richard L Sidman | Frederick F Lang | Frank B Furnari | Webster K Cavenee | E. Barbu | Leo G Flores | Michael G Ozawa | S. Soghomonyan | Oliver Bogler | Vincenzo Paolillo | Wouter H P Driessen | Catherine A Moya | Fernanda I Staquicini | E Magda Barbu | Suren Soghomonyan | Catherine A. Moya | F. Staquicini
[1] D. Choudhury,et al. Tertiary structural changes associated with iron binding and release in hen serum transferrin: a crystallographic and spectroscopic study. , 2004, Biochemical and biophysical research communications.
[2] R. MacGillivray,et al. Inequivalent contribution of the five tryptophan residues in the C-lobe of human serum transferrin to the fluorescence increase when iron is released. , 2009, Biochemistry.
[3] I. Trowbridge,et al. Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.
[4] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[5] W. Pardridge,et al. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.
[6] W. Banks. Are the Extracellular Pathways a Conduit for the Delivery of Therapeutics to the Brain , 2004 .
[7] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[8] H. Davson. Blood–brain barrier , 1977, Nature.
[9] A. Mason,et al. Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor , 2009, JBIC Journal of Biological Inorganic Chemistry.
[10] W. Pardridge. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. , 2008, Bioconjugate chemistry.
[11] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[12] W. Arap,et al. Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU , 2007, Nature Protocols.
[13] Kim-Anh Do,et al. Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.
[14] Thomas Walz,et al. Structure of the Human Transferrin Receptor-Transferrin Complex , 2004, Cell.
[15] I. Verma,et al. Targeted delivery of proteins across the blood–brain barrier , 2007, Proceedings of the National Academy of Sciences.
[16] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[17] W. Pardridge,et al. Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.
[18] W. Pardridge. Drug Targeting to the Brain , 2007, Pharmaceutical Research.
[19] Emmanuel Dias-Neto,et al. Next-Generation Phage Display: Integrating and Comparing Available Molecular Tools to Enable Cost-Effective High-Throughput Analysis , 2009, PloS one.
[20] B. Zlokovic. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.
[21] W. Pardridge,et al. A One‐Step Procedure for Isolation of Poly(A)+ mRNA from Isolated Brain Capillaries and Endothelial Cells in Culture , 1991, Journal of neurochemistry.
[22] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[23] W. Pardridge,et al. Marked enhancement in gene expression by targeting the human insulin receptor , 2003, The journal of gene medicine.
[24] W. Banks,et al. Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[25] R. MacGillivray,et al. Ligand-induced conformational change in transferrins: crystal structure of the open form of the N-terminal half-molecule of human transferrin. , 1998, Biochemistry.
[26] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[27] W. Pardridge,et al. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[28] W. Arap,et al. Design and construction of targeted AAVP vectors for mammalian cell transduction , 2007, Nature Protocols.
[29] Kim-Anh Do,et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. , 2006, Cancer research.
[30] J. Nutt,et al. Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.
[31] G. Baldwin. Comparison of transferrin sequences from different species. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.
[32] H. Baker,et al. Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. , 1998, Biochemistry.
[33] R Weissleder,et al. Measuring transferrin receptor gene expression by NMR imaging. , 1998, Biochimica et biophysica acta.
[34] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[35] C. Lilley,et al. A Hybrid Vector for Ligand-Directed Tumor Targeting and Molecular Imaging , 2006, Cell.
[36] R. Sidman,et al. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. , 2008, Trends in cardiovascular medicine.
[37] W. Banks. Delivery of peptides to the brain: emphasis on therapeutic development. , 2008, Biopolymers.
[38] J. Humm,et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. , 1998, Cancer research.
[39] W. Arap,et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging , 2008, Proceedings of the National Academy of Sciences.
[40] R. MacGillivray,et al. Intrinsic fluorescence reports a global conformational change in the N-lobe of human serum transferrin following iron release. , 2007, Biochemistry.
[41] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[42] Wadih Arap,et al. Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.
[43] Z. M. Shen,et al. Conformational stability of porcine serum transferrin , 1992, Protein science : a publication of the Protein Society.
[44] R. Starzyk,et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[45] G. Fuller,et al. An implantable guide-screw system for brain tumor studies in small animals. , 2000, Journal of neurosurgery.
[46] G. Reifenberger,et al. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction , 2005, Virchows Archiv A.
[47] C. Merril,et al. Fate of Bacteriophage Lambda in Non-immune Germ-free Mice , 1973, Nature.
[48] L. Recht,et al. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. , 1990, Journal of neurosurgery.
[49] O. L. Davies,et al. Studies on the blood-brain barrier; the basis of dosage for animals of various weights. , 1948, British journal of pharmacology and chemotherapy.
[50] W. Pardridge,et al. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse , 2009, Biotechnology and bioengineering.
[51] R. Broadwell,et al. Endocytic and exocytic pathways of the neuronal secretory process and trans synaptic transfer of wheat germ agglutinin‐horseradish peroxidase in vivo , 1985, The Journal of comparative neurology.
[52] G. Fuller,et al. Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study , 2006, Technology in cancer research & treatment.
[53] W. Pardridge,et al. Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.